An observational, retrospective, cohort study analyzing epidemiology, treatment patterns, and clinical outcomes in de novo oligometastatic hormone-sensitive prostate cancer
Latest Information Update: 30 Mar 2023
At a glance
- Drugs Abiraterone (Primary) ; Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
Most Recent Events
- 30 Mar 2023 New trial record
- 18 Feb 2023 Results presented at the 2023 Genitourinary Cancers Symposium